Together with the Chinese Antibody Society, Biointron's latest webinar features Shun Zhou, Ph.D, the R&D Director at Cyagen:
“Accelerating Antibody Discovery with Fully Human Antibody Mouse HUGO-Ab™ and Single B Cell Screening Technology AbDrop™”
This topic explores the revolutionary potential of the genome-edited mouse HUGO-Ab, where endogenous VH and VL genes are replaced by fully human VH and VL genes in situ, enabling the generation of fully human antibody molecules. When combined with microfluidic technology-enhanced single B cell screening, this approach allows for the high-throughput and efficient discovery of antibody drug molecules.
About the Speaker:
Shun Zhou has a Ph.D. in Molecular Biology and Genetics from the Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, and is a Postdoctoral Fellow in the Department of Biomedical Engineering at Tufts University, USA. With over 10 years of research and development experience in molecular biology, cell biology, and genetics, his work has been published in more than 10 articles in journals such as PNAS and Acta Biomaterialia. Currently serving as the R&D Director at Cyagen Bioscience, he has extensive project research experience in gene editing technologies, Gene and Cell therapy drug research technologies, and antibody discovery technologies, participating in several preclinical projects for antibody drugs and gene and cell therapy drugs.
DOI: 10.3389/fbioe.2022.856049Antibodies have become essential tools for the diagnosis and treatment of numerous human diseases. However, non-human antibodies, such as those derived from murine sources, often provoke human anti-mouse antibody (HAMA) responses. This immunogenicity leads to rapid clea
In therapeutic antibody development, achieving high-affinity antigen binding is central to improving drug efficacy, durability, and safety.Biointron’s High-Throughput Fully Human Antibody Discovery service is designed to meet this need by integrating advanced screening and engineering technol
I. Introduction to Hybridoma TechnologyHybridoma technology, developed by Köhler and Milstein in 1975, is a foundational method for producing monoclonal antibodies (mAbs). The approach involves fusing antibody-producing B lymphocytes with immortal myeloma cells to form hybridoma cells. These hybrid
Introduction to Monoclonal Antibody Discovery Monoclonal antibodies (mAbs) are one of the most successful classes of biologic drugs on the global pharmaceutical market. Since the approval of Orthoclone OKT3 in 1986, over 100 mAbs have been approved by the U.S. FDA for indications incl
ScientistとScience Exchangeとのご利用可能です。
